Answers are grounded in this paper and cite their sources.
Observational study assessed Acro-PREV's effectiveness for acromegaly diagnosis in outpatient settings, indicating its potential utility.
Background and Aim: Acromegaly (ACRO) is characterized by increased release of growth hormone and, consequently, insulin-like growth factor I (IGF1), most often by a pituitary adenoma. The estimated prevalence is 40-125 cases/million but targeted universal screening studies have found a higher prevalence (about 10 fold). The aim of the present study was to investigate the usefulness of Acro-PREV questionaire to diagnosis ACRO between patients attending general medical outpatient.Methods: The Acro-PREV investigate the main symptoms, physical changes and comorbities of ACRO. A self-administered questionnaire was provided to patients attending general medical outpatient. IGFI was measured in patients with ≥1 acral symptom/ physical changes and ≥2 comorbidities.Results: Of the 200 patients enrolled, 54 patients (27%) were tested for IGF1, 1 case of ACRO were diagnosed. A male patient of 54 year old were diagnosed of acromegaly due to a pituitary macroadenoma GH-secreting.Conclusions: In conclusion ACRO-PREV could be an useful tool for ACRO diagnosis, however further studies are needed on larger populations.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: